Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation

Cancer Science

Volumn 106, Issue 10, 2015, Pages 1429-1437

  Huo, Zhi Jun ^a   Wang, Shi Jiang ^a   Wang, Zhi Qi ^a   Zuo, Wen Shu ^a   Liu, Ping ^b   Pang, Bo ^c   Liu, Kai ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Breast cancer; Drug delivery; Hybrid nanoparticles; Lapatinib

Indexed keywords

LAPATINIB; LIPID; NANOPARTICLE; POLYMER; SUCCINIC ACID; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; DRUG CARRIER; LACTIC ACID; MACROGOL DERIVATIVE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; QUINAZOLINE DERIVATIVE; TOCOFERSOLAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER TISSUE; CELL PROLIFERATION; CIRCULATION TIME; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MCF 7 CELL LINE; MOUSE; NONHUMAN; PH; POLYMERIZATION; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; TREATMENT OUTCOME; TUMOR CELL; TUMOR VOLUME; TUNEL ASSAY; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; HUMAN; MCF-7 CELL LINE; METABOLISM; MONONUCLEAR PHAGOCYTE; NUDE MOUSE; PHAGOCYTOSIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; HUMANS; LACTIC ACID; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; MONONUCLEAR PHAGOCYTE SYSTEM; NANOPARTICLES; PHAGOCYTOSIS; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; QUINAZOLINES; TUMOR BURDEN; VITAMIN E; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939631175     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12737     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. DeSantis CE, Lin CC, Mariotto AB et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64: 252-71.
3. Crozier JA, Swaika A, Moreno-Aspitia A. Adjuvant chemotherapy in breast cancer: to use or not to use, the anthracyclines. World J Clin Oncol 2014; 5: 529-38.
4. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5: 161-71.
5. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triplenegative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721-8.
6. Tan DS, Marchio C, Jones RL et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008; 111: 27-44.
7. Martin V, Botta F, Zanellato E et al. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol Histopathol 2012; 27: 785-92.
8. Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005; 24: 6213-21.
9. Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21: 6255-63.
10. Budha NR, Frymoyer A, Smelick GS et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther 2012; 92: 203-13.
11. Burris HR, Taylor CW, Jones SF et al. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 2009; 15: 6702-8.
12. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010; 7: 653-64.
13. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev 2004; 56: 1649-59.
14. Lee SM, Ahn RW, Chen F et al. Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. ACS Nano 2010; 4: 4971-8.
15. Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle technologies for oral drug delivery. Clin Gastroenterol Hepatol 2014; 12: 1605-10.
16. Mukherjee B, Satapathy BS, Mondal L, Dey NS, Maji R. Potentials and challenges of active targeting at the tumor cells by engineered polymeric nanoparticles. Curr Pharm Biotechnol 2013; 14: 1250-63.
17. Madni A, Sarfraz M, Rehman M et al. Liposomal drug delivery: a versatile platform for challenging clinical applications. J Pharm Pharm Sci 2014; 17: 401-26.
18. Wang Y, Kho K, Cheow WS, Hadinoto K. A comparison between spraydrying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles. Int J Pharm 2012; 424: 98-106.
19. Gao J, Xia Y, Chen H et al. Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma. Nanomedicine (Lond) 2014; 9: 279-93.
20. Zhang L, Chan JM, Gu FX et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2008; 2: 1696-702.
21. Ma Y, Zheng Y, Liu K et al. Nanoparticles of poly(lactide-co-glycolide)-d-a-tocopheryl polyethylene glycol 1000 succinate random copolymer for cancer treatment. Nanoscale Res Lett 2010; 5: 1161-9.
22. Constantinou C, Papas A, Constantinou AI. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int J Cancer 2014; 123: 739-52.
23. Ruttala HB, Ko YT. Liposomal co-delivery of curcumin and albumin/paclitaxel nanoparticle for enhanced synergistic antitumor efficacy. Colloids Surf B Biointerfaces 2015; 128: 419-26.
24. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2013; 63: 170-83.
25. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008; 30: 1426-47.
26. Zhang F, Braun GB, Pallaoro A et al. Mesoporous multifunctional upconversion luminescent and magnetic "nanorattle" materials for targeted chemotherapy. Nano Lett 2012; 12: 61-7.